Ironwood Pharmaceuticals (IRWD)
(Real Time Quote from BATS)
$8.28 USD
+0.29 (3.63%)
Updated Apr 23, 2024 01:20 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
IRWD 8.28 +0.29(3.63%)
Will IRWD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IRWD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IRWD
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
IRWD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable
Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet
Other News for IRWD
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)
First Week of June 21st Options Trading For Ironwood Pharmaceuticals (IRWD)
Ironwood management to meet with Craig-Hallum
Ironwood management to meet with Craig-Hallum
Piper Sandler Reaffirms Their Buy Rating on Ironwood Pharma (IRWD)